The 5 most recent market catalysts affecting $GRDN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Keybanc Initiates Coverage On Guardian Pharmacy Service with Overweight Rating, Announces Price Target of $52
Keybanc analyst Zach Haggerty initiated coverage on Guardian Pharmacy Service (GRDN) with an 'Overweight' rating and a $52 price target. This event is significant as it introduces …
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Guardian Pharmacy Service, Raises Price Target to $51
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Guardian Pharmacy Service (GRDN) and raised the price target from $47 to $51. This action signals continued c…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Oppenheimer Maintains Outperform on Guardian Pharmacy Service, Raises Price Target to $49
Oppenheimer analyst Michael Wiederhorn has raised the price target for Guardian Pharmacy Service (GRDN) from $43 to $49 while maintaining an 'Outperform' rating. This action signal…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Guardian Pharmacy Service Q2 Adj. EPS $0.29 Beats $0.27 Estimate, Sales $351.768M Beat $340.045M Estimate
Guardian Pharmacy Service (GRDN) announced Q2 adjusted EPS of $0.29, surpassing the $0.27 consensus estimate, and sales of $351.768 million, exceeding the $340.045 million estimate…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Guardian Pharmacy Service Raises FY2026 Sales Guidance from $1.400B-$1.420B to $1.430B-$1.450B vs $1.415B Est
Guardian Pharmacy Service (GRDN) has filed an 8-K to announce an upward revision to its FY2026 sales guidance, moving from an initial range of $1.400 billion-$1.420 billion to a ne…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.